Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 1;5(2):263-264.
doi: 10.1001/jamaoncol.2018.5621.

Treatment of Metastatic Prostate Cancer in 2018

Chung-Han Lee  1 , Philip Kantoff  2
Affiliations

Treatment of Metastatic Prostate Cancer in 2018

Chung-Han Lee et al. JAMA Oncol. .
No abstract available

PubMed Disclaimer

Figures

Figure.
Figure.. Suggested Treatment Paradigm for Molecular Biomarkers in Advanced Prostate Cancer
ADT indicates androgen deprivation therapy; mCRPC, metastatic castration-resistant prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer; nmHSPC, nonmetastatic hormone-sensitive prostate cancer.
See this image and copyright information in PMC

References

    1. Kyriakopoulos CE Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–1087. doi:10.1200/JCO.2017.75.3657 - DOI - PMC - PubMed
    1. James ND, Sydes MR, Clarke NW, et al.; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177 doi:10.1016/S0140-6736(15)01037-5 - DOI - PMC - PubMed
    1. Gravis G Boher JM, Joly F, et al.; GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: Impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2): 256–262. doi:10.1016/j.eururo.2015.11.005 - DOI - PubMed
    1. Fizazi K, Tran N, Fein L, et al.; LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360. doi:10.1056/NEJMoa1704174 - DOI - PubMed
    1. James ND, de Bono JS, Spears MR, et al.; STAMPEDE Investigators. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351. doi:10.1056/NEJMoa1702900 - DOI - PMC - PubMed

MeSH terms